Transplantation of Autologously Derived Mitochondria Following Ischemia
Transplantation of Autologously Derived Mitochondria for Protection Against Ischemia-reperfusion Injury Following Ischemia in Subjects on ECMO Support
Boston Children's Hospital
16 participants
Aug 2, 2017
INTERVENTIONAL
Conditions
Summary
The investigators propose a robust therapeutic intervention to ameliorate myocardial ischemia/ reperfusion injury and significantly decrease morbidity and mortality in patients requiring extracorporeal membrane oxygenation (ECMO), by direct injection of autogeneic mitochondria into the ischemic myocardium.
Eligibility
Inclusion Criteria2
- Pediatric cardiology patients under the age of 18 on ECMO
- concerns for ischemic injury on the Cardiac Intensive Care Unit
Exclusion Criteria1
- Known mitochondria disorders
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Autologous mitochondria obtained from the subject's own skeletal muscle will be injected or infused into the ischemic myocardium
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02851758